drugset
drugset / Trial / NCT00059618

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

NCT00059618 ↗

Phase 1 Completed 21 enrolled M.D. Anderson Cancer Center Millennium Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest safe dose of PS-341 that can be given with carboplatin chemotherapy as a treatment for patients with ovarian, abdominal, or fallopian tube cancer. Researchers also hope to find out if giving these drugs together will help shrink or slow the growth of tumors in patients who are considered resistant to platinum drugs. The safety of these drugs will also be studied.

Timeline

Start
2003-04
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 0.8 mg/m2 Intravenous
Subject Carboplatin Small molecule — Intravenous

Indications

fallopian tube cancer ovarian cancer primary peritoneal carcinoma